CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hotte, Sebastien
  • Winquist, E
  • Chi, KN
  • Ellard, SL
  • Sridhar, S
  • Emmenegger, U
  • Salim, M
  • Iqbal, NN
  • Canil, C
  • Kollmannsberger, CK
  • Hansen, AR
  • Lalani, Aly-Khan
  • Gingerich, J
  • Finch, D
  • Cabanero, M
  • Wyatt, AW
  • Tu, D
  • Vera-Badillo, F
  • Seymour, LK
  • Smoragiewicz, M

publication date

  • October 2019